Anlon Healthcare Limited has informed the Exchange about Amendment(s) in Share Purchase Agreement dated November 28, 2025, in relation to acquisition of stake in Bizotic Life Science Private Limited.
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anlon Healthcare Limited has amended its Share Purchase Agreement (SPA) dated November 28, 2025, for acquiring a 56.67% stake in Bizotic Lifescience Private Limited. The amendment, signed on February 27, 2026, extends the deadline for completing the acquisition to April 2, 2026, which is 125 days from the original execution date. The extension is due to certain pending procedural requirements. The deal itself remains active and has not been cancelled or restructured in terms of stake size.
This is a procedural update extending the timeline of an already-disclosed acquisition; the deal is still on track but delayed. Shareholders should note the closure is now pushed to early April 2026, and any near-term stock reaction is likely to be muted unless further changes to deal terms are announced.